Described herein are compounds and methods of using nitric oxide (NO) generating compositions with a phosphodiesterase inhibitor of a phosphodiesterase that hydrolyzes cyclic guanosine monophosphate (cGMP) to improve the efficacy and decrease the side effects of these inhibitors.